Lactoferrin/Talactoferrin / P53 Cancer Research Results

LF, Lactoferrin/Talactoferrin: Click to Expand ⟱
Features:
Lactoferrin is a protein in human and animal milk that helps regulate iron absorption and fight infections.Found in milk, saliva, tears and nasal secretions.
***"Most studies have shown similar or superior efficacy of bLF to traditionally used therapy (ferrous sulfate and ferric hydroxide) in restoring iron deficiency, with significantly fewer gastrointestinal side effects"

Lactoferrin — Lactoferrin (LF, Lf) is an approximately 80-kDa iron-binding glycoprotein of the transferrin family that is abundant in human and bovine milk and is also present in saliva, tears, mucosal secretions and neutrophil granules. It functions as an innate-defense, iron-homeostasis and immunoregulatory protein rather than as a conventional small-molecule drug. Commercial supplements predominantly use bovine lactoferrin (bLF), whereas talactoferrin alfa is a recombinant human lactoferrin that has undergone oncology clinical trials. Lactoferricin is a bioactive peptide generated by proteolysis of lactoferrin and can have stronger direct membrane-disruptive anticancer effects than intact LF. Lactoferrin is available in licensed natural-health products in Canada, but it is not an approved anticancer treatment. Anticancer effects are strongly context-, formulation- and tumor-dependent.

-Talactoferrin alfa is recombinant human lactoferrin (rhLF) developed specifically as an oral pharmaceutical/immunotherapy. Its amino-acid sequence corresponds to human lactoferrin, whereas most commercial lactoferrin supplements are bovine lactoferrin (bLF). Human and bovine LF are homologous and share the same broad iron-binding protein architecture

Primary mechanisms (ranked):

  1. Modulation of iron availability and iron-redox homeostasis, potentially limiting iron-dependent tumor growth and altering oxidative signaling.
  2. Antitumor immune modulation, including activation or recruitment of NK cells, T cells, dendritic cells and other innate/adaptive immune components, particularly through gut-associated lymphoid tissue after oral administration.
  3. Induction of tumor-cell apoptosis and cell-cycle arrest through pathways including p53, caspases, mitochondrial apoptosis, AKT/mTOR and JAK/STAT3, with substantial tumor- and model-dependence.
  4. Suppression of invasion, migration, EMT and metastasis through effects on TGF-β and other motility-associated signaling pathways.
  5. Suppression of angiogenesis and tumor-supportive inflammatory signaling in several experimental models.
  6. Inhibition of plasmalemmal V-H+-ATPase in some highly metastatic cancer cells, reducing extracellular acidification and disrupting tumor-cell pH homeostasis.
  7. Direct membrane-disruptive cytotoxicity, particularly for the lactoferricin peptide rather than intact lactoferrin.
  8. Context-dependent regulation of ferroptosis. Although iron restriction may be anticancer in many settings, recent prostate-cancer evidence indicates endogenous lactoferrin can increase ferritin and suppress p53-ALOX12-mediated ferroptosis, potentially promoting tumor progression in that specific biological context.

Bioavailability / PK relevance: Oral intact lactoferrin has limited and variable systemic bioavailability because the protein is susceptible to gastric and intestinal proteolysis. Biological activity after oral administration does not necessarily require high circulating intact LF because local intestinal receptors and gut-associated immune tissues can mediate systemic immunologic effects. Enteric protection, liposomes, nanoparticles and other encapsulation approaches can improve stability and delivery. Recombinant talactoferrin used gram-level oral doses in oncology trials. Bovine LF doses in the principal colorectal-polyp RCT were 1.5 or 3 g/day.

In-vitro vs systemic exposure relevance: Many direct tumor-cell experiments expose cells to approximately tens to hundreds of micrograms per mL, and some studies use substantially higher concentrations. These direct extracellular concentrations should generally not be assumed to be achievable as circulating intact LF after ordinary oral supplementation. Gastrointestinal tumors and mucosal immune tissues can experience much greater local exposure after oral administration, making colorectal and gut-mediated immunologic findings more pharmacologically plausible than extrapolation of high-concentration cell-culture effects to distant tumors.

Clinical evidence status: Predominantly preclinical with limited human evidence. A randomized placebo-controlled trial in patients with small colorectal adenomas found that 3 g/day bovine LF for one year reduced polyp growth in a prespecified younger subgroup, but this is prevention-oriented evidence rather than treatment of established colorectal cancer. A small randomized adjunct study in colorectal-cancer patients receiving chemotherapy did not demonstrate a significant between-group clinical benefit. Recombinant human talactoferrin produced encouraging phase I/II signals in NSCLC and renal-cell carcinoma, but the large phase III FORTIS-M NSCLC trial was negative for overall survival, progression-free survival and disease control. Lactoferrin therefore has no established or approved role as systemic anticancer therapy. Oral bovine LF is generally well tolerated; important practical precautions include cow's-milk protein allergy/hypersensitivity and product-specific contraindications.

Lactoferrin Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Iron availability and iron homeostasis ↓ labile iron availability ↔ / regulated iron handling R-G Restricts iron-dependent proliferation and modifies redox signaling Central biochemical property of LF; effects depend on iron saturation, tumor iron demand and cellular handling of LF.
2 Antitumor immune response ↑ immune-mediated tumor killing ↑ NK, T-cell and dendritic-cell activity (context-dependent) G Enhances tumor immune surveillance Especially important for orally administered LF and talactoferrin because gut-associated lymphoid tissue can mediate effects without requiring high systemic intact-protein exposure.
3 Apoptosis ↑ caspase activation, ↑ Bax, ↓ BCL-2 ↔ / substantially less cytotoxicity in several models G Promotes programmed tumor-cell death Mitochondrial and receptor-associated mechanisms have been reported; selectivity varies among tumor types.
4 AKT mTOR survival signaling ↓ AKT, ↓ mTOR signaling ↔ (model-dependent) R-G Reduces survival and proliferative signaling Demonstrated in gastric and oral squamous carcinoma models; not established as a universal LF response.
5 p53 and cell-cycle control ↑ p53, ↑ G0/G1 or G1/S arrest ↔ (model-dependent) G Suppresses proliferation Reported in OSCC and hepatocellular carcinoma models and linked to apoptosis in responsive cells.
6 JAK STAT3 signaling ↓ STAT3 signaling ↔ (context-dependent) R-G Reduces prosurvival and proliferative signaling SOCS3 activation and reduced JAK/STAT3 signaling have been demonstrated in oral squamous carcinoma cells.
7 EMT and TGF-β signaling ↓ EMT, ↓ TGF-β-associated signaling ↓ pathological EMT (context-dependent) G Reduces invasive phenotype and supports epithelial integrity The existing Nestronics entry emphasizes this axis, but its current evidence set contains only one associated paper and should not be treated as the dominant overall anticancer mechanism.
8 Migration invasion and metastasis ↓ migration, ↓ invasion, ↓ metastasis ↔ G Suppresses metastatic behavior Supported by multiple experimental models; mechanisms include EMT regulation, immune effects and modification of tumor acidity.
9 V-H+-ATPase and tumor acidity ↓ plasmalemmal V-H+-ATPase, ↓ extracellular acidification ↔ in tested non-tumorigenic cells R Disrupts pH regulation in highly metastatic cells Mechanistically compelling but demonstrated particularly in V-H+-ATPase-rich metastatic breast-cancer models rather than across cancers generally.
10 Angiogenesis ↓ tumor vascularization ↔ / context-dependent G Restricts tumor blood supply Most evidence remains preclinical; effects may partly reflect immune and inflammatory modulation.
11 ROS and oxidative stress ↔ / ↓ oxidative stress (context-dependent) ↓ excessive oxidative stress R-G Modifies iron-driven redox biology LF usually acts as an iron-buffering antioxidant, but redox consequences vary with iron saturation, cell type and treatment conditions. ROS elevation is not a universal primary LF anticancer mechanism.
12 Lactoferricin membrane disruption ↑ membrane permeabilization and cytotoxicity Lower susceptibility in many models P-R Direct tumor-cell killing Primarily attributable to lactoferricin and related cationic LF-derived peptides; should not automatically be assigned to intact oral LF.
13 Ferroptosis ↓ ferroptosis in prostate cancer (context-dependent) Iron-redox homeostasis G Potentially protects selected cancer cells from ferroptotic death A 2026 prostate-cancer study found an AR-LF-ferritin axis that suppressed p53-ALOX12-mediated ferroptosis and accelerated tumorigenesis. This is an important exception to treating LF as universally anticancer.
14 Chemosensitization ↑ chemotherapy response (model-dependent) Potential protection from chemotherapy toxicity (preclinical) G Potential adjunct effect Strong responses have been demonstrated in animal models, especially with iron-saturated LF, but convincing human therapeutic benefit has not been established.
15 Clinical Translation Constraint Variable Generally well tolerated G Limits translation of experimental anticancer findings Intact oral LF undergoes gastrointestinal degradation; systemic exposure is low and variable. Many direct cell-culture concentrations exceed plausible circulating exposure. Human oncology evidence is limited, and phase III talactoferrin treatment of refractory NSCLC was negative.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Alzheimer's disease relevance: Lactoferrin has preliminary neuroprotective evidence in Alzheimer's disease (AD), including cellular and animal models and one small randomized human pilot study. Proposed effects include reduced amyloidogenic processing and Aβ burden, reduced tau phosphorylation, suppression of neuroinflammation and oxidative stress, and enhancement of neuronal survival signaling through PI3K/Akt, ERK/CREB and ADAM10-associated pathways. A 50-patient pilot study reported improvements in cognitive scores and several circulating AD-associated biomarkers after 3 months of lactoferrin supplementation. Evidence remains preliminary and has not been confirmed in large replicated clinical trials; published reviews also identify inconsistent experimental findings.

AD clinical evidence status: Small human pilot study plus preclinical evidence; not an established AD treatment.

Lactoferrin in Alzheimer's Disease

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Amyloidogenic processing and Aβ ↓ Aβ production / accumulation Potential reduction of amyloid pathology Linked to altered amyloid-processing pathways including ADAM10 and, in experimental studies, reduced amyloidogenic enzyme activity. Evidence is primarily preclinical.
2 PI3K Akt PTEN signaling ↑ PI3K, ↑ Akt, ↑ p-Akt, ↓ PTEN Promotes neuronal survival and suppresses pathological stress signaling A central pathway identified in the small human AD pilot study.
3 Tau phosphorylation ↓ p-tau Potential reduction of tau-associated pathology Reduced circulating p-tau and tau were reported in the human pilot study; CNS disease-modifying significance remains uncertain.
4 Neuroinflammation ↓ IL-6 and inflammatory signaling Reduces inflammatory stress Consistent with the broader immunomodulatory properties of lactoferrin.
5 Oxidative stress ↓ oxidative stress Protects neurons from oxidative injury Likely involves iron sequestration and modulation of cellular antioxidant pathways.
6 ERK CREB signaling ↑ ERK CREB signaling Supports neuronal survival, plasticity and memory-associated signaling Mainly supported by mechanistic and preclinical literature.
7 ADAM10 and non-amyloidogenic APP processing ↑ ADAM10 Favors non-amyloidogenic APP processing Potential mechanism for reducing Aβ generation; predominantly preclinical evidence.
8 Cognitive function ↑ cognitive performance Potential symptomatic or disease-modifying benefit Improved MMSE and ADAS-Cog measures were reported in one small human study; replication is required.
9 Clinical Translation Constraint Uncertain Limits confidence in therapeutic relevance Human evidence is based largely on one small study. CNS exposure of orally administered intact lactoferrin and the optimal formulation, dose and treatment duration remain uncertain.


P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
8134- LF,    Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways
- in-vitro, CRC, HT-29
Iron↓, Apoptosis↑, selectivity↑, Casp8↑, P53↑, P21↑,
8140- LF,    Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
P53↑, AChE↑, Ach↓, VEGF↓, Akt↓,
8131- LF,    Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma
- in-vitro, OS, HSC2 - in-vitro, OS, HSC3 - in-vitro, OS, HSC4 - in-vitro, Nor, RT7
P53↑, Akt↓, SOCS-3↑, mTOR↓, JAK↓, STAT3↓, selectivity↑, TumCP↓, Iron↓, TumCCA↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Iron↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 1,   Casp8↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

JAK↓, 1,   SOCS-3↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

selectivity↑, 2,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
3 Lactoferrin/Talactoferrin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:111  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page